CAPhO 2024 Sponsored Symposium Lilly - Beyond the Basics: Strategies for Counseling and Managing Adverse Events Associated with Adjuvant CDK4/6 Inhibitor Therapy

In early breast cancer (eBC), HR+ and HER2- treatments are evolving with maturing data in the adjuvant setting. Understanding the risk/benefits of CDK4/6 inhibitors use in eBC and establishing clear expectations for the patient is key toward achieving optimal care and adherence.

A multidisciplinary panel, consisting of a medical oncologist and pharmacists, will discuss clinical evidence and case-based scenarios. In their discussion, they will highlight the importance of a collaborative approach toward counselling, education, and management of the patient on adjuvant CDK4/6 inhibitor treatment for improved patient outcomes.

Learning Objectives:

• Understand the factors that may be prognostic of a higher risk of cancer recurrence in patients with early breast cancer (eBC) and how this impacts management approaches.
• Review the treatment landscape of adjuvant CDK4/6 inhibitors in eBC and current approaches to patient counselling.
• Discuss multidisciplinary team strategies to optimize therapy and patient experience with CDK4/6 inhibitors in the adjuvant setting for eBC, including ways to counsel, educate and manage adverse events (AEs).
• Discuss follow up pathways to assist with AE management and explore the role of dose reduction to assist with adherence to treatment.

Sponsored by Lilly